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Introduction 
The treatment of small renal masses (SRMs) represents an area of increasing interest. Since the initial 
description of NSS, a number of technical strategies for tumor excision have been described. These 
strategies can be grouped into three main categories: simple enucleation (SE), enucleoresection (ER), 
also referred to as standard partial nephrectomy (SPN)), and wedge resection (WR). SPN is defined as 
the excision of the tumor and of an additional margin of healthy peritumoral renal parenchyma, while 
SE as the excision of the tumor by blunt dissection following the natural cleavage plane between the 
peritumoral pseudocapsule and the renal parenchyma without removing a visible rim of healthy renal 
tissue.  
 
Enucleative partial nephrectomy: long-term results 
Surgical approach: Enucleative PN has been first described as an open technique but it can be feasible 
also during the laparoscopic or the robotic procedure. A matched-pair analysis of 392 patients treated 
with SE for T1a-T1b renal tumors, including 160 patients in the open group and 80 in the robotic group 
(Endoscopic Robotic Assisted Simple Enucleation, ERASE), showed that ERASE is a feasible technique 
with a positive surgical margin rate comparable to the open technique; it showed WIT and complication 
rates similar to the open approach, along with the advantages of mini-invasivity [3]. 
 
Indications 
SE can be used for the elective treatment of sporadic renal masses regardless tumor dimension [4], but 
also for relative and absolute indications to NSS [4, 5]. It is has been reported a possible advantage using 
SE especially when facing tumors with most unfavourable nephrometry (PADUA ≥ 10; RENAL ≥ 10, totally 
endorenal tumors, cT1b with endophytic growth into the medulla and close to main intrarenal vessels 
and collecting system). However, the majority of the studies on the perioperative results of TE does not 
analyse subgroups of challenging tumors [6-8]. In a recent study, that assessed the perioperative results 
of SE in 244 patients, a substantial 21% had a PADUA score ≥10 thus confirming that SE might wide the 
technical indications of NSS including the most challenging cases [9]. With the advent of nephrometric 
scores, it would be important in the future to further test the efficacy of SE for the treatment of tumors 
with adverse nephrometric scores and to compare the results with those of standard PN [10,11]. 
 
Exclusion criteria to enucleative partial nephrectomy: High Fuhrman grade (Fuhrman grade 4) might be 
a contraindication for SE. Indeed, a recent paper from the SATURN project showed that patients who 
underwent SE for Fuhrman grade 4 disease had significantly worse cancer specific survival compared to 
those undergoing standard PN but patients were too few (20 Standard PN versus 4 SE) to make this 
observation nothing more than a suggestion for future studies [6]. 
 
Warm ischemia time (WIT), functional outcomes and perioperative complications:  Some Authors have 
hypothesized that SE might be associated with shorter WIT and could be protective against complications 
being possibly associated with a lower rate of major bleeding and urinary fistula compared to standard 
PN [10]. Indeed, SE showed in single center prospective series a low incidence of postoperative 
complications requiring reintervention, a low rate of urinary fistulas and of ureteral stenting [7, 9].  
However, in a large multicenter prospectively derived dataset (RECORd project), a matched-pair 
comparison of 396 patients showed that SE and standard PN are associated with similar WIT and similar 
incidence of overall, surgical and medical complications [8].  In the same study, SE was associated with 
shorter operative time and lower blood loss if compared to standard PN [8]. No comparative data on 
mid- and long-term functional outcomes between SE and standard PN have been reported to date. 
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Surgical margin status 
The achievement of negative surgical margins is one of the major challenges of NSS. PSM after NSS 
occurs in 0-8% of patients. The presence of PSM as risk factor for disease recurrence after NSS is still a 
matter of debate, however, it should prompt more frequent and intensive surveillance. The incidence of 
positive surgical margins has been consistently very low in SE series [13, 14]. The protective effect of a 
blunt enucleation towards the risk of positive margins has been demonstrated in a prospective 
pathological study on 90 RCCs that  showed the presence of an inflammatory tissue with a median 
thickness of 1mm which allowed the presence of negative surgical margins also for tumors 
microscopically extending beyond the tumor capsule [15].  This thin layer of   normal tissue was present 
as “leopard spots” on the intact tumor capsule, and always present in case of neoplastic penetration of 
the capsule into the kidney tissue [15]. A recent prospective study on 304 patients evaluated the 
prognostic effect of capsule penetration on local recurrence after SE [16].  At a median (range) follow-up 
of 52 months (12–96), there was no statistically significant difference in progression-free survival (PFS) 
between patients with an intact tumor capsule and those who had neoplastic penetration of the capsule 
into the kidney tissue (5-year PFS 97.5% and 96.7%, respectively) [16].  In the latter the crude local 
recurrence rate was 3.2% [16].  Two recent multicentre papers have showed a significantly lower 
incidence of PSM after SE when compared to standard PN [4, 8]. Longo et al. in the first multicentre 
matched-pair analysis aiming to compare the perioperative outcomes of SE versus standard PN in 
clinical T1 renal tumors showed that the incidence of positive margins was significantly lower in patients 
treated with SE and 4.7 higher in pts undergoing standard PN [8]. In this regard we can conclude that SE 
is at least non inferior to standard PN  for what concern the risk of positive margins; however, further 
studies using a standardized classification of different NSS techniques are warranted to render definitive 
conclusions regarding the risk of positive margins with different types of NSS. 
 
Oncologic outcomes, from pathology reports to mid- and long-term follow up studies: The oncologic 
safety of blunt SE has been demonstrated by retrospective studies which demonstrated that the width of 
the surgical margin was not associated with the oncological prognosis and by prospective pathological 
studies [15-17]. Several retrospective studies have confirmed good oncologic results of SE and some of 
these studies have demonstrated also a similar local recurrence-free survival and cancer specific survival 
rates between SE and standard PN, for renal tumors with clinical diameter up to 7 cm; one study have 
also confirmed similar cancer specific survival between SE and radical nephrectomy [18-25].  
 
Future perspectives 
Unfortunately, standardized definitions for each resection technique during NSS are lacking. Indeed, the 
descriptors SE, ER, and WR are used largely interchangeably. The precise resection methodology is 
rarely reported in the published series, despite a relationship between technique and complication 
rates, preserved parenchymal volume, surgical margins (SMs), local recurrence, and oncologic 
outcomes. The main limitation of such definitions is that they are based on the surgeon’s preoperative 
resection strategy rather than the actual postoperative surgical result (resection technique). In this 
context, a more thoughtful vision of tumor excision during partial nephrectomy would be to clearly 
divide the concepts of the surgeon’s resection strategy from that of the actual resection technique. The 
surgeon’s resection strategy can be conceptually divided into two clearly defined options according to 
the resection plane developed for tumor excision. Indeed, the preoperative intent of the surgeon 
(resection strategy) can be described as anatomic or nonanatomic according to the dissection plane 
chosen by the surgeon, being anatomic when the natural cleavage plane between the tumor with its 
pseudocapsule and the normal healthy parenchima, is developed. While, the actual postoperative 
surgical result (resection technique) could be classified according to a careful analysis of the specimen 
after surgery. In this regard, the Surface-Intermediate-Base (SIB) Margin score was recently proposed to 
provide the literature with a standardized reporting system of resection techniques during NSS and we 
recently validated the model from the histopathological perspective [1,2]. We have shown that the visual 
definitions of resection techniques used to calculate the score do significantly mirror histopathological 
analysis to quantify and report the thickness of healthy renal margin resected by the surgeon. In the final 
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analysis, the SIB score represents a simple tool to classify the true, post-operative resection technique. 
In conclusion, in order to describe accurately the complexity of tumor excision, each PN should include a 
definition of both resection strategy (anatomic vs nonanatomic) and resection technique (pure or hybrid 
enucleation, pure or hybrid enucleoresection and resection) according to the SIB classification system. 
Dividing the concepts of resection strategy and resection technique will allow the surgeon to describe 
the complexity of each tumor excision during NSS in the very best way. 
 
Conclusions 
In summary, the long-terms results of enucleative PN are at least comparable to SPN with regard to both 
oncological efficacy and surgical safety. However, 1) the lack of standardized terminology to describe 
NSS techniques; 2) the current inability to communicate the complexity that may be inherent in a given 
tumor’s resection, and (3) the nearly complete absence of routine reporting of resection type potentially 
may undermine the interpretation of NSS outcomes and may prohibit meaningful comparisons of results 
among surgeons and institutions.  
 
As such, we believe standardized definitions of both the surgeon’s preoperative intent and the actual 
postoperative surgical result (resection technique, according to the SIB score) should be mandatory in 
future series to significantly raise the quality of the reported NSS data making outcome assessments and 
comparisons more meaningful. 
 
Further research is needed to define the best surgical strategy and technique for PN in each individual 
patient. As such, prospective high-quality studies are needed. However, whether a randomized 
controlled trial is really needed is still controversial, as many methodological and conceptual limitations 
associated with the randomization process may undermine the overall interpretation of the final results. 
In particular, since the preoperative intent of the surgeon does not necessarily translate into the 
expected resection technique, it would be complex to assign each tumor resection to enucleation or 
enucleoresection a priori. Accordingly, a well-designed, prospective cohort study including a detailed 
reporting of both resection strategy and technique might be the most thoughtful answer to this 
controversial topic.  
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